2016 American Transplant Congress
CXCL12 as Innovative Immune Isolating Chemokine for Microencapsulated Allo and Xeno-Transplantation in NHPs.
Introduction The purpose of this study is to determine whether a clinical-grade alginate-microencapsulant incorporating CXCL12, can protect and sustain the function of allo and/or adult…2016 American Transplant Congress
Indirect Allo-Antigen Stimulation Identifies the Presence of Either Regulatory IL-10 or of Effector Cytokines IFN-g, IL-21, IL-17a Production by Human Blood Allo-Reactive Memory TFH and TCONV CD4+ T Cells.
Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA.
Background: It is well accepted that human CD4+ T cell allo-immunity plays pivotal roles during cellular and humoral allograft rejection. While our previous analysis showed…2016 American Transplant Congress
Pancreas Retransplantation – Is It Worth It?
Background: Pancreas transplantation is well established therapy for insulin-dependent diabetic patients. Management of patients with failed graft by retransplantation might be associated with increased technical…2016 American Transplant Congress
Low Risk of Cytomegalovirus (CMV) Transmission in Clinical Islet Transplantation.
Background:In solid organ transplantation (SOT), CMV is commonly transmitted from seropositive organ donors (D+) to seronegative recipients (R-), despite the use of antiviral prophylaxis. The…2016 American Transplant Congress
Tolerance Induction in Vascularized Composite Allotransplantation with Peri-Transplant Combined Costimulation Blockade.
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss, such…2016 American Transplant Congress
Intravenous Immunoglobulins Failed to Prevent Acute Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo DSA within the First Year After Transplant.
BackgroundAround 25% of kidney transplant recipients develop de novo anti-HLA donor specific antibodies (DSA). Most of them are detected within the first year after transplant.…2016 American Transplant Congress
Comparison of Renal Outcomes Between ABO-Incompatible and Kidney Paired Donation Transplantation In Living Donors.
Kidney Transplant Unit, UCSF, San Francisco, CA.
Introduction: ABO incompatible transplantation (ABOi Tx) broadens the donor pool and decreases wait times for patients who don't have a blood type compatible living kidney…2016 American Transplant Congress
Pre-Formed AT1R Antibodies Are Associated with Rejection After Kidney Transplantation.
Nephrology, University of Washington, Seattle.
Antibody mediated injury is a significant contributor to rejection and allograft damage. Non-HLA antibodies have been increasingly recognized in association with graft dysfunction. Our goal…2016 American Transplant Congress
Exposure Analysis for the Composite Efficacy Endpoints in the US92 Phase 3 Kidney Transplantation Trial to Understand Center Effects.
The US92 study determined whether, in de novo renal transplant patients, concentration-controlled everolimus (EVR) with reduced dose tacrolimus (RTAC) is non-inferior compared to CellCept®, (mycophenolate…2016 American Transplant Congress
Analysis of T Cell Receptor Repertoire in Routine Renal Allograft Biopsy.
Introduction: Diversity and clonality of the T cell repertoire of circulating and tissue-resident T-cells can be assessed by sequencing of recombined T cell receptor (TCR)…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 180
- Next Page »